News about "Takeda "

Insilico Medicine and Takeda Collaborate on AI Drug Discovery

Takeda and Insilico Medicine are collaborating to advance Artificial Intelligence (AI)-powered drug discovery, leveraging the Pharma.AI platform to accelerate the development of therapeutics.

Takeda | 02/07/2026 | By News Bureau

Takeda's Oveporexton Improves Daily Function in Narcolepsy Type 1

Takeda’s phase 3 data show oveporexton improved daily function, cognition, and nighttime sleep in people with narcolepsy type 1. The results support the potential of the first orexin agonist therapy, with regulatory submissions currently under review.

Takeda | 16/06/2026 | By News Bureau

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Takeda | 08/04/2026 | By News Bureau |  119

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Takeda | 30/03/2026 | By News Bureau |  198

Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1

FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.

Takeda | 11/02/2026 | By News Bureau |  173

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Takeda | 19/12/2025 | By News Bureau |  133

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Takeda | 05/12/2025 | By Dineshwori |  153

Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata

Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.

Takeda | 01/09/2025 | By Dineshwori |  240

BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs

Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.

Takeda | 26/02/2025 | By Aishwarya |  473

Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan

HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.

Takeda | 31/12/2024 | By Aishwarya |  413